论文部分内容阅读
目的观察阿苯达唑壳聚糖微球(ABZ-CS-MPs)治疗小鼠继发性泡状棘球蚴病的疗效。方法将继发性泡状棘球蚴病随机分组,其中治疗组分别给予ABZ-CS-MPs和阿苯达唑脂质体(L-ABZ),剂量均为75mg/(kg·d),模型对照组不作治疗。用小鼠灌胃针经口每周灌胃3次,连续灌胃6周、9周后(期间死亡12只)分批处死各组小鼠,取肝脏作大体形态观察;取泡球蚴组织,囊湿重,计算抑囊率;取泡球蚴组织制片,作病理组织学观察;取小鼠血,分离血清,采用ELISA法检测IL-2、IL-10含量。结果 ABZ-CS-MPs组灌胃6、9周后的抑囊率分别为87.83%和90.21%。病理组织观察ABZ-CS-MPs对泡球蚴组织的损伤较L-ABZ组严重。血清IL2模型对照组接种12周、15周后分别为(18.529±1.496)pg/ml和(19.040±1.439)pg/ml,空白对照组12周、15周后分别为(30.057±3.425)pg/ml和(31.507±3.124)pg/m,差异有统计学意义(P<0.05);L-ABZ组灌胃6周、9周后分别为(22.153±3.112)pg/ml和(23.373±4.549)pg/ml,ABZ-CS-MPs灌胃6周、9周后分别为(25.871±4.318)pg/ml和(27.154±3.205)pg/ml,与模型对照组比较差异有统计学意义(P<0.05)。血清IL-10模型对照组接种12周、15周后分别为(14.841±3.761)pg/ml和(16.728±1.739)pg/ml,空白对照组12周、15周后分别为(8.006±4.531)pg/ml和(7.606±2.863)pg/ml,差异有统计学意义(P<0.05);L-ABZ组灌胃6周、9周后为(11.324±2.676)pg/ml和(13.342±2.633)pg/ml,ABZ-CS-MPs组灌胃6周、9周后为(8.057±0.801)pg/ml和(10.519±3.233)pg/ml,与模型对照组差异有统计学意义(P<0.05)。ABZ-CS-MPs组IL-2与L-ABZ组比较差异有统计学意义(P<0.05),IL-10与L-ABZ组比较差异有统计学意义(P<0.05)。结论ABZ-CS-MPs治疗小鼠AE效果优于L-ABZ,并可提高泡球蚴小鼠Th1免疫水平。
Objective To observe the efficacy of albendazole chitosan microspheres (ABZ-CS-MPs) in the treatment of secondary alveolar hydatid disease in mice. Methods The secondary alveolar hydatid disease were randomly divided into groups, in which ABZ-CS-MPs and albendazole liposomes (L-ABZ) were given to the treatment group at doses of 75mg / (kg · d) Control group without treatment. Mice were given oral gavage 3 times a week orally, continuous gavage for 6 weeks, 9 weeks (12 died during the period) mice were sacrificed in batches and the general morphology of the liver was observed; take Echinococcus granulosus tissue The wet weight of the bladder was calculated to calculate the inhibition rate. The cysticercus cellulosae tissue preparation was made for histopathological observation. The blood of the mice was taken and the serum was separated. The levels of IL-2 and IL-10 were detected by ELISA. Results The abomasum rates of ABZ-CS-MPs group after oral administration for 6 and 9 weeks were 87.83% and 90.21%, respectively. Pathological observation of ABZ-CS-MPs of Echinococcus granulosus tissue damage than the L-ABZ group. Serum IL2 model control group was (12.529 ± 1.496) pg / ml and (19.040 ± 1.439) pg / ml after inoculation for 12 weeks and 15 weeks respectively, and the control group was (30.057 ± 3.425) pg / ml, and (31.507 ± 3.124) pg / m, respectively (P <0.05); L-ABZ group was (22.153 ± 3.112) pg / ml and (23.373 ± 4.549) (25.871 ± 4.318) pg / ml and (27.154 ± 3.205) pg / ml, respectively, compared with the model control group (P < 0.05). Serum IL-10 was 12.8 weeks after vaccination in the control group, and (14.841 ± 3.761) pg / ml and (16.728 ± 1.776) pg / ml after 15 weeks of inoculation. The control group was (8.006 ± 4.531) (11.324 ± 2.676) pg / ml and (13.342 ± 2.633) pg / ml, respectively (P <0.05). The difference was statistically significant (P <0.05) ) pg / ml, ABZ-CS-MPs group was 6 weeks after gavage, and (8.057 ± 0.801) pg / ml and (10.519 ± 3.233) pg / ml after 9 weeks respectively. The difference was statistically significant between the model group and the control group (P < 0.05). The difference between IL-2 and L-ABZ group was statistically significant (P <0.05) in ABZ-CS-MPs group, and there was significant difference between IL-10 and L-ABZ group (P <0.05). CONCLUSION: ABZ-CS-MPs are superior to L-ABZ in the treatment of AE in mice and enhance the level of Th1 immunity in BALB / c mice.